GMV and New Radiant Technology sign a global agreement for radiance TPS distribution

New Radiant Technology, leader manufacturer of mobile linear accelerators for intra-operative radiotherapy, and GMV, multinational engineering firm successfully operating in various high technology markets and recognized as a highly innovative and competitive solution provider, have today announced an agreement whereby New Radiant Technology will market GMV’s radiotherapy treatment planning system for intra-operative radiotherapy (IORT) as part of its linear accelerator package.

This agreement reinforces New Radiant Technology’s portfolio, making it the only mobile linear accelerator manufacturer that provides a complete solution for the implementation of an IORT procedure in hospitals. It also extends GMV’s distribution capability, facilitating its ambition of reaching every current IORT user as well as increasing the hospital takeup of this highly beneficial technique.

Intraoperative radiation therapy is a technique for targeting a large single radiation dose at the tumor bed during surgery, immediately after tumor removal (when the tumor is found to be unresectable, the IORT dose is used as a boost, with or without post-operative external beam RT). The radiation is focused directly on the anatomical area that contained the neoplasia, a possible location of sub-clinical disease or macroscopic residue.

The technical advantages of the IORT technique include direct visual control of the target volume and the possibility of protecting the surrounding healthy tissue, by simply moving or shielding it from the radiation beam. Electron beams can be delivered in a homogeneous dose at a controlled depth of the tissue layer of the tumor bed. Local control is always high and toxicity is greatly reduced.

The Report of AAPM’s Radiation Therapy Committee Task Group No. 72 of 2005 identified the need for treatment planning systems. Until the advent of radiance this was just not available in the market.

radiance is the perfect simulation and planning tool to assist radiation oncologists, surgeons, physicists and other IORT professionals, offering all the following:
- Predictive and registered IORT planning: dosimetry estimation, calculation and reporting.
- Improved communication to define the radio-surgical decision-making process with an individualized approach for each particular cancer patient.

Prof. Felipe Calvo, oncology department director of the Gregorio Marañón University Hospital, recently indicated that ‘the system enhances the documentation of the process for posterior analysis’.

Prof. Roberto Orecchia, radiotherapy division director of the European Institute of Oncology, has recently defined Radiance as an ‘important step forward in the history of IORT’, adding that ‘the preplanning phase is an important improvement in IORT treatment of breast cancer’.